We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Levels of NfL Increase Accuracy of Stroke Risk Prediction

By LabMedica International staff writers
Posted on 08 Jul 2019
Serum levels of neurofilament light polypeptide have been found to predict the likelihood of suffering a stroke and to add considerably to the discriminatory power of the Framingham Stroke Risk Score in a group of middle-aged and older adults with diabetes mellitus.

Neurofilament light polypeptide (NfL), also known as neurofilament light chain, is a neurofilament protein that in humans is encoded by the NEFL gene. More...
Neurofilament light chain is a biomarker that can be measured with immunoassays in cerebrospinal fluid and blood serum and plasma that reflects axonal damage in a wide variety of neurological disorders. It is a useful marker for disease monitoring in amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, and more recently Huntington's disease.

As effective stroke prevention depends on accurate stroke risk prediction, investigators at the University of Michigan (Ann Arbor, USA) examined the discriminative ability of NfL levels for distinguishing between adults with diabetes mellitus who developed incident stroke and those who remained stroke free during a seven-year follow-up period.

The investigators performed a case-control study of participants selected from the previously completed ACCORD trial (Action to Control Cardiovascular Risk in Diabetes). The 113 cases were all ACCORD subjects who were stroke free at enrollment and developed incident stroke during follow-up. A group of 250 control subjects comprised randomly selected ACCORD subjects who had no stroke events either before or after randomization. NfL levels were measured in baseline samples using Quanterix (Billerica, MA, USA) Single Molecule Array technology.

Results revealed that subjects who developed a stroke had blood levels of NfL that were about 43% higher than those who did not develop a stroke. In contrast, those with the highest NfL levels were 10 times more likely to develop a stroke during the seven-year follow-up period, than those with low levels of NfL.

In addition, the results showed that older age, nonwhite race, higher systolic blood pressure, glomerular filtration rate less than 60, and higher hemoglobin A1C were independent predictors of serum NfL in this cohort, but that diastolic blood pressure, durations of hypertension or diabetes mellitus, and lipid levels were not.

First author Dr. Frederick Korley, assistant professor of emergency medicine at the University of Michigan, said, "The Framingham Stroke Risk Score looks at stroke risk factors in a patient and predicts 10-year probability of a stroke occurring. The score currently includes factors such as diabetes, current smoking status, and blood pressure. When we added NfL levels as a risk factor, the score appeared to become even more accurate in predicting stroke."

The NfL study was published in the July 1, 2019, issue of the journal Stroke.

Related Links:
University of Michigan
Quanterix


New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Collection and Transport System
PurSafe Plus®
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
New
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.